Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02600585 · ClinicalTrials.gov registry record
Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults
A clinical trial, sponsored by Protein Sciences Corporation.
- Completed
- Registry status
- 254,648
- Enrollment target
NCT02600585 is a clinical trial that has completed, run by Protein Sciences Corporation. The registered enrollment target is 254,648 participants.
The verdict
NCT02600585 has completed, sponsored by Protein Sciences Corporation.
- COMPLETED
- Registry status
- 254,648 participants
- Enrollment target
Study Summary
The primary objective of this study is to retrospectively characterize the safety of Flublok in adults 18 years of age and older, in comparison with egg-based trivalent or quadrivalent inactivated influenza vaccines (IIVs), using a methodological approach designed to query the database of electronic health records (EHR) maintained by Kaiser-Permanente, Northern California (KPNC), a large medical care organization (MCO).
Interventions
- BIOLOGICAL Inactivated Influenza Vaccine
- BIOLOGICAL Recombinant Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254,648 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02600585
The ClinicalTrials.gov registry entry for NCT02600585 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 254,648 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Protein Sciences Corporation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Inactivated Influenza Vaccine is the first listed.
NCT02600585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02600585 about?
NCT02600585 is a clinical study titled "Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults". The primary objective of this study is to retrospectively characterize the safety of Flublok in adults 18 years of age and older, in comparison with egg-based trivalent or quadrivalent inactivated influenza vaccines (IIVs), using a methodological approach designed to query the database of electronic...
What is the current status of trial NCT02600585?
This trial is currently completed. The enrollment target is 254,648 participants. The study started on 2015-11. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02600585?
The interventions under investigation include: Inactivated Influenza Vaccine (BIOLOGICAL), Recombinant Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02600585?
This trial is sponsored by Protein Sciences Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.